AAAAAA

   
Results: 1-10 |
Results: 10
Macrocyclic immunosuppressants
Authors: Keller, TH Hersperger, R Della Cioppa, G
Citation: Th. Keller et al., Macrocyclic immunosuppressants, PROG R RES, 31, 2001, pp. 237-240
Clinical efficacy with formoterol in the absence of a response to salmeterol: A review
Authors: Kottakis, J Wood, R Le Gros, V Della Cioppa, G
Citation: J. Kottakis et al., Clinical efficacy with formoterol in the absence of a response to salmeterol: A review, INT J CL PR, 55(7), 2001, pp. 476-479
A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler
Authors: Bensch, G Lapidus, RJ Levine, BE Lumry, W Yegen, U Kiselev, P Della Cioppa, G
Citation: G. Bensch et al., A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler, ANN ALLER A, 86(1), 2001, pp. 19-27
Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease
Authors: Dahl, R Greefhorst, LAPM Nowak, D Nonikov, V Byrne, AM Thomson, MH Till, D Della Cioppa, G
Citation: R. Dahl et al., Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease, AM J R CRIT, 164(5), 2001, pp. 778-784
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. (vol 18, pg 254, 2001)
Authors: Soler, M Matz, J Townley, R Buhl, R O'Brien, J Fox, H Thirlwell, J Gupta, N Della Cioppa, G
Citation: M. Soler et al., The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. (vol 18, pg 254, 2001), EUR RESP J, 18(4), 2001, pp. 739-740
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
Authors: Soler, M Matz, J Townley, R Buhl, R O'Brien, J Fox, H Thirlwell, J Gupta, N Della Cioppa, G
Citation: M. Soler et al., The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics, EUR RESP J, 18(2), 2001, pp. 254-261
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
Authors: Busse, W Corren, J Lanier, BQ McAlary, M Fowler-Taylor, A Della Cioppa, G van As, A Gupta, N
Citation: W. Busse et al., Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma, J ALLERG CL, 108(2), 2001, pp. 184-190
Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis
Authors: Adelroth, E Rak, S Haahtela, T Aasand, G Rosenhall, L Zetterstrom, O Byrne, A Champain, K Thirlwell, J Della Cioppa, G Sandstrom, T
Citation: E. Adelroth et al., Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis, J ALLERG CL, 106(2), 2000, pp. 253-259
Sustained bronchoprotection, bronchodilatation, and symptom control duringregular formoterol use in asthma of moderate or greater severity
Authors: FitzGerald, JM Chapman, KR Della Cioppa, G Stubbing, D Fairbarn, MS Till, D Brambilla, R
Citation: Jm. Fitzgerald et al., Sustained bronchoprotection, bronchodilatation, and symptom control duringregular formoterol use in asthma of moderate or greater severity, J ALLERG CL, 103(3), 1999, pp. 427-435
Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of foradil dry powder inhalation via Aerolizer (TM)
Authors: Lecaillon, JB Kaiser, G Palmisano, M Morgan, J Della Cioppa, G
Citation: Jb. Lecaillon et al., Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of foradil dry powder inhalation via Aerolizer (TM), EUR J CL PH, 55(2), 1999, pp. 131-138
Risultati: 1-10 |